



Neonatal Abstinence Syndrome



Jeff Cooper, MD
October 26th, 2021

Disclosures

- None



Objectives

- Define NAS and NOWS
- Understand Prevalence of NAS/NOWS
- Identify Clinical Presentation of NAS/NOWS
- Discuss Both Nonpharmacologic & Pharmacologic Management of NAS/NOWS
- Implement Best Practices for Discharge and Follow-up of Newborn with NAS/NOWS

Define NAS/NOWS

- NAS – Neonatal Abstinence Syndrome
- NOWS – Neonatal Opioid Withdrawal Syndrome
- Both terms used interchangeably
- More recently NOWS used for infants born to opioid-using mothers
- More recently NAS used for infants born to polysubstance-using mothers

Define NAS/NOWS

- Clinical diagnosis
- Consequence of abrupt discontinuation of a chronic fetal exposure to substances used during pregnancy
- Multisystem disorder
 - Central and autonomic nervous systems
 - Gastrointestinal tract


Define NAS/NOWS

- For the purposes of this lecture, I will use NAS exclusively to refer to any infant born to a mother using one or multiple substances legally or illegally during her pregnancy that has withdrawal symptoms.

Prevalence of NAS

- Seven newborns for every 1,000 newborns are diagnosed with NAS in the US
- 80 newborns per day

Prevalence of NAS Wyoming




Rate per 1,000 live births

Data source: WY Hospital Discharge Data

Prevalence of NAS Montana

Chart

Neonatal Withdrawal Syndrome and NWS, By Year, Montana 2006-2015



Clinical Presentation of NAS

- Signs vary by drug use
- Severity of withdrawal may not correlate with dose or duration of exposure
- Narcotics provide the earliest studies and clearest picture
- Spectrum includes morphine, heroin, methadone, prescription opioids, antidepressants, anxiolytics and/or other substances

Narcotics/Barbiturates

- Opioid involvement from birth to 10-14 days
- Barbiturates delayed from 4 days to 4 months
- Involved systems commonly involved
 - Central Nervous System
 - Gastrointestinal
 - Autonomic Nervous System
- Other lesser involved systems
 - Respiratory
 - Integumentary

Opioids (CNS)

- Hypertonia
- Tremors
- Hyperreflexia
- Irritability
- Restlessness
- High-pitched cry
- Sleep disturbances
- Occasionally seizures

Opioids (Autonomic)

- Sweating
- Low-grade fever
- Nasal stuffiness
- Sneezing
- Yawning
- Skin mottling

Opioids (GI)

- Diarrhea
- Vomiting
- Poor feeding
- Poor swallowing
- Failure to thrive

Pathophysiology of opioids

- Not well known
- Opiate drugs easily transfer across the placenta
- Transmission increases as gestation increases
- Withdrawal may worsen based on ease of crossing the blood-brain barrier and prolonged half-life



Pathophysiology of opioids


- Complex biological phenomenon
- Most complex in neonates vs adults
 - Immature neurologic development
 - Impaired neurologic processing
 - Complex materno-feto-placental pharmacokinetics

Pathophysiology of opioids

- Opioid activity in locus coeruleus of the pons
 - Sensitive to opioid status
- Lack of opioids leads to increased production of norepinephrine
- Ventral tegmental area of the midbrain simultaneously releases less dopamine
- Decreased serotonin release in dorsal raphe nucleus which causes sleep disturbances

Pathophysiology of opioids

- Increased production of other neurotransmitters such as acetylcholine
- May activate HPA axis leading to increased corticotrophin release



Stimulants

- Methamphetamine and cocaine
- Less likely to need pharmacologic treatment
- May represent direct effect of stimulant itself
 - Tremors
 - High-pitched cry
 - Irritability
 - Excess suck
 - Hyperalert
 - Apnea
 - Tachypnea
- Higher rate of prematurity, IUGR, and asphyxia
- Complicated by polydrug use

Depressants/Sedatives

- EtOH withdrawal begins 3-12 hours after delivery
- Can see physical findings of FASD
- Severity of NAS much lower
- Sedative-hypnotics present a few days after birth

SSRIs

- Up to 33% of infant affected
- Signs include tremors, increased muscle tone, sleep disruption, GI disturbance, and high-pitched crying
- Symptoms usually self-limited and lasts 2-4 days

Toxicology confirmation

- Necessary to identify the substance
- Meconium
 - Most sensitive than urine testing
 - Window of detection from 20 weeks
- Urine
 - More popular
 - Window of detection a few days
- Cord or hair samples
 - Require reference lab

Reporting

- Case Management
- State-specific laws
- https://www.childwelfare.gov/pubPDFs/parental_substanceuse.pdf

Reporting



STATE STATUTES
CURRENT THROUGH JULY 2019

Parental Substance Use as Child Abuse

To find statute information for a particular State, go to
<https://www.childwelfare.gov/topics/systemwide/laws-policies/state/>.

Management Approach

- Multidisciplinary approach
- Goals
 - Promote infant and parental regulation
 - Minimize signs of NAS

Abstinence Scoring Systems

- Finnegan scoring system
 - 20 signs in neurologic, respiratory and GI categories
 - 1-7 mild symptoms
 - 8 or more severe symptoms
- Neonatal Withdrawal Scoring System
- Ostrea criteria
- Neonatal Withdrawal Inventory
- Riley Infant Pain Scale

Abstinence Scoring Systems

- Quantifying the severity of NAS helps determine need for pharmacologic therapy
- Scoring assists in monitoring, titrating, and terminating therapy
- Best after feeds, at 3-4 hours intervals, while infant is awake
- Useful for term infant, but not for preterm infants

Nonpharmacological Care

- Sufficient in cases of mild withdrawal
- Gentle handling, demand feedings, swaddling, and ambient noise control
- Swaddling lessens stimulation and decreases crying time
- Minimal stimulation includes dim light and low noise
- Frequent feedings and high-calorie formula or breast milk

Nonpharmacological Care

- Eat Sleep Console assessment evaluates
 - Ability to take 1 oz or more per feeding
 - Sleep undisturbed for 1 hour or more
 - Be consoled in under 10 minutes
- Emphasizes maternal involvement and decreases length of stay and use of opioid therapy
- Further study for safety and effectiveness are needed

Pharmacological Care

- No uniformly accepted pharmacologic intervention or standardized treatment
- Medication required when
 - Supportive therapy fails
 - Withdrawal scores remain high
 - Serious signs are observed, such as seizures
 - Severe dehydration such as diarrhea or vomiting
- Delays in treatment associated with higher morbidity and longer hospital stays

Pharmacological Care

- Opioid antagonists, naloxone, contraindicated due to seizure risk
- Paregoric or tincture of opium have toxic chemicals and high alcohol content
- Sedative have prolonged half-life and associated complications

Pharmacological Care

- Morphine most common preferred medication
- Decreases incidence of seizures, improves feeding, eliminates diarrhea, decreases agitation, and can control severe symptoms
- Prolongs hospital stay
- Treatment must be provided every 3-4 hours
- Quickly escalate for rising scores with a gradual wean

Pharmacological Care

- Methadone alternative to morphine
- Administered twice per day
- Dose can be increased or decreased depending on severity score
- Buprenorphine newer option starting to be used – high 30% alcohol content

Pharmacological Care

- Adjunctive therapies
- Clonidine
 - Adjunctive therapy for opioid therapy for NAS
 - Decreases length of stay
- Phenobarbital
 - Decreases length of stay
 - No safety profile and alcohol content is a concern

Discharge and Follow Up

- Withdrawal signs are diminished, infant is feeding well, sleeping well, and gaining weight
- Evaluate
 - Parental functioning and mental health
 - Support for substance use disorder treatment
 - Home environment and support systems
- Follow up within 48 hours to establish care
 - Possible ophthalmologic eval for strabismus, nystagmus and refractory errors
 - Neurodevelopmental assessment

References

- Velez M, Jansson LM. The Opioid dependent mother and newborn dyad: non-pharmacologic care. J Addict Med 2008; 2:113.

<https://www.cdc.gov/pregnancy/opioids/data.html>. Center for Disease Control and Prevention

DHHR Wyoming. <https://health.wyo.gov/wp-content/uploads/2020/01/NAS-brief-v5.pdf>

Agency for Healthcare Research and Quality. <https://www.hcup-us.ahrq.gov/faststats/NASServlet?setting1=IP&location1=MI>

Montana Public Health Information System. <http://ibis.mt.gov/indicator/view/DrugNAS.Rate.Year.html>

Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134:e547.

Patrick SW, Barfield WD, Poindexter BB, COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON SUBSTANCE USE AND PREVENTION. Neonatal Opioid Withdrawal Syndrome. Pediatrics 2020; 146.

Parlaman J, Deodhar P, Sanders V, et al. Improving Care for Infants With Neonatal Abstinence Syndrome: A Multicenter, Community Hospital-Based Study. Hosp Pediatr 2019; 9:608.

